Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.
New York, US
Size (employees)
116 (est)
Synergy Pharmaceuticals is headquartered in New York, US

Synergy Pharmaceuticals Office Locations

Synergy Pharmaceuticals has an office in New York
New York, US (HQ)
420 Lexington Ave

Synergy Pharmaceuticals Data and Metrics

Synergy Pharmaceuticals Financial Metrics

Synergy Pharmaceuticals's revenue was reported to be $0 in 2016

Net income (Y, 2016)

(198.6 m)

EBIT (Y, 2016)

(42.4 m)

Market capitalization (23-Jun-2017)

1.1 b

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

82.4 m
Synergy Pharmaceuticals's current market capitalization is $1.1 b.
USDFY, 2013FY, 2014FY, 2015Y, 2016


(176.8 m)(94.3 m)(99.8 m)(42.4 m)

Net Income

(171.2 m)(95.7 m)(117.5 m)(198.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


18.1 m146.5 m61.7 m82.4 m


3.7 m3.8 m3.3 m5.6 m

Current Assets

71.9 m200.2 m115.1 m88.9 m


589 k642 k531 k593 k

Total Assets

72.6 m213.3 m115.9 m89.9 m

Accounts Payable

13.5 m13.9 m13.3 m15.6 m

Current Liabilities

15.7 m18.3 m19.6 m29.4 m

Additional Paid-in Capital

226.5 m261.7 m329.2 m620.5 m

Retained Earnings

(171.2 m)(266.9 m)(384.4 m)(583 m)

Total Equity

55.3 m(5.2 m)(55.2 m)37.5 m

Financial Leverage

1.3 x-41.4 x-2.1 x2.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(62.1 m)(95.7 m)(117.5 m)(198.6 m)

Depreciation and Amortization

56 k120 k163 k233 k


(2.2 m)(124 k)531 k(5.6 m)

Accounts Payable

7.1 m316 k1.9 m11.5 m

Cash From Operating Activities

(52.6 m)(89.1 m)(101 m)(129.8 m)

Purchases of PP&E

(615 k)(173 k)(50 k)(297 k)

Cash From Investing Activities

(30.9 m)282 k(250 k)49.8 m

Cash From Financing Activities

89.2 m217.1 m16.4 m100.7 m

Income Taxes Paid

81 k55 k258 k45 k
Y, 2016

Financial Leverage

2.4 x

Synergy Pharmaceuticals Operating Metrics

Synergy Pharmaceuticals's Patent Applications was reported to be 3 in FY, 2016
FY, 2016

Patents (US)


Patent Applications


Patents (foreign)


Patents Pending


Synergy Pharmaceuticals Market Value History

Synergy Pharmaceuticals Online and Social Media Presence

Synergy Pharmaceuticals News and Updates

Synergy Pharmaceuticals Company Life and Culture

You may also be interested in